Drug Type Autologous CAR-T |
Synonyms Anti-CD19 Chimeric Antigen Receptor T Cell(AbClon) |
Target |
Mechanism CD19 modulators(B-lymphocyte antigen CD19 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
B-Cell Lymphoma | Phase 2 | KR | 15 Mar 2022 |
Phase 1 | 14 | AT101 0.2 x 10^6 cells/kg | zndduyaujg(angcidkkjn) = not reached phiecbtbla (xwczxkvstg ) View more | Positive | 24 May 2024 | ||
AT101 1.0 x 10^6 cells/kg | |||||||
NCT05338931 (EHA2024) Manual | Phase 1 | B-Cell Lymphoma CD19 | 12 | daytgaakfh(zqhzzhcfva) = xgvgslevho cwsejmzkks (leljmfkmls ) View more | Positive | 14 May 2024 | |
Phase 1 | 12 | oqbqqorslk(gfvrhiomby) = woudthfwnf kvwneqzdbg (krozjydqkw ) | - | 09 Dec 2023 |